CAS 496775-61-2|Eltrombopag

Introduction：Basic information about CAS 496775-61-2|Eltrombopag, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Eltrombopag BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Eltrombopag
CAS Number	496775-61-2	Molecular Weight	442.467
Density	1.3±0.1 g/cm3	Boiling Point	656.8±65.0 °C at 760 mmHg
Molecular Formula	C₂₅H₂₂N₄O₄	Melting Point	242-244ºC
MSDS	/	Flash Point	351.0±34.3 °C

Names

Name	eltrombopag
Synonym	More Synonyms

Eltrombopag BiologicalActivity

Description	Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.
Related Catalog	Signaling Pathways >>Immunology/Inflammation >>Thrombopoietin ReceptorResearch Areas >>Cardiovascular Disease
References	[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. [2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. [3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. [4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41. [5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

Description

Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Related Catalog

Signaling Pathways >>Immunology/Inflammation >>Thrombopoietin ReceptorResearch Areas >>Cardiovascular Disease

References

[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.

[2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.

[3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36.

[4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41.

[5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

Chemical & Physical Properties

Density	1.3±0.1 g/cm3
Boiling Point	656.8±65.0 °C at 760 mmHg
Melting Point	242-244ºC
Molecular Formula	C₂₅H₂₂N₄O₄
Molecular Weight	442.467
Flash Point	351.0±34.3 °C
Exact Mass	442.164093
PSA	114.59000
LogP	3.70
Vapour Pressure	0.0±2.1 mmHg at 25°C
Index of Refraction	1.667

Safety Information

HS Code	2933990090

Customs

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

Eltrombopag

3'-{(2E)-2-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid

3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid

(E)-Eltrombopag

[1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2E)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-

SB-497115-GR

Recommended......